Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A squamous cell carcinoma arising from the mucosa of the anal canal.
Biomarker and diagnostic research for anal canal squamous cell carcinoma has been reported in the published literature.
3 clinical trials registered. Interventions under study include other interventions, procedural interventions, drug therapy, and biologic therapy. Pipeline includes 2 PHASE2. Research is primarily sponsored by academic and government institutions.
37 publications have been identified in PubMed for anal canal squamous cell carcinoma. Research spans Clinical Trial Publication (30%), Case Report / Case Series (22%), and Epidemiology / Natural History (19%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 11 |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 12:16 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
30%
Patient case studies | 8 | 22% |
Disease patterns and progression | 7 | 19% |
Research summaries | 5 | 14% |
Laboratory research | 4 | 11% |
Other research | 1 | 3% |
Testing and diagnosis research | 1 | 3% |
Matsumura N (2026). [PMID: 41504991](https://pubmed.ncbi.nlm.nih.gov/41504991/). *International journal of clinical oncology*. [Other]
Marcon LR (2026). [PMID: 41534233](https://pubmed.ncbi.nlm.nih.gov/41534233/). *Explore (New York, N.Y.)*. [Case Report / Case Series]
Awad A (2026). [PMID: 42066269](https://pubmed.ncbi.nlm.nih.gov/42066269/). *Pain Med Case Rep*. [Case Report / Case Series]
Rao S (2026). [PMID: 42097353](https://pubmed.ncbi.nlm.nih.gov/42097353/). *Ann Oncol*. [Clinical Trial Publication]
Tomaciello M (2026). [PMID: 41708358](https://pubmed.ncbi.nlm.nih.gov/41708358/). *Clinical colorectal cancer*. [Case Report / Case Series]
Morris VK (2026). [PMID: 41499716](https://pubmed.ncbi.nlm.nih.gov/41499716/). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. [Clinical Trial Publication]
Yamada K (2026). [PMID: 41452529](https://pubmed.ncbi.nlm.nih.gov/41452529/). *International journal of clinical oncology*. [Epidemiology / Natural History]
Garm Spindler KL (2026). [PMID: 42109075](https://pubmed.ncbi.nlm.nih.gov/42109075/). *Acta Oncol*. [Epidemiology / Natural History]
Camandaroba MPG (2026). [PMID: 41994010](https://pubmed.ncbi.nlm.nih.gov/41994010/). *ESMO Gastrointest Oncol*. [Clinical Trial Publication]
Kondo A (2025). [PMID: 40360405](https://pubmed.ncbi.nlm.nih.gov/40360405/). *Gan to kagaku ryoho. Cancer & chemotherapy*. [Case Report / Case Series]
AI-curated news mentioning anal canal squamous cell carcinoma
Updated Jun 3, 2026
A recent case study highlights an unusual presentation of anal squamous cell carcinoma, emphasizing the need for awareness and early diagnosis. This case contributes to the understanding of rare cancer manifestations.
The European Commission has approved Incyte's treatment for advanced squamous cell anal carcinoma (SCAC), marking the first systemic therapy available for adults with this condition. This approval represents a significant advancement in treatment options for patients suffering from advanced anal cancer.
EMA recommends extending the indication of Zynyz (retifanlimab) for treating advanced squamous cell carcinoma of the anal canal in adults. This marks a significant step in immunotherapy options for this patient population.